Wellgistics Health

WGRX

Market cap $8.85M

Trading under new symbol (NASDAQ: MEDS) completes corporate rebranding from prior corporate name Wellgistics Health (NASDAQ: WGRX) TAMPA, FL / ACCESS Newswire / July 22, 2026 / DataMEDS AI, Inc., (NASDAQ:MEDS, "DataMEDS," or the "Company"), a Health IT company leveraging its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contacts platform PharmacyChain™ to provide integrated solutions for the generation, rationalization, intervention, transaction and monetization of health data, today announced that it has officially completed its stock trading symbol change to ‘MEDS'. The Company began trading under the new stock symbol ‘MEDS' on the NASDAQ Capital Market stock exchange effective at the start of trading on Wednesday, July 22, 2026.

Leading Health IT Company's Rebranding Reflects Updated Healthcare Ecosystem Aligned with AI Integration to Optimize Patient Control of Healthcare Data TAMPA, Fla., July 21, 2026 /PRNewswire/ -- Wellgistics Health, Inc., (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™, today announced that it has officially completed its name change to  DataMEDS AI, Inc. ("DataMEDS" or  "the Company").

TAMPA, FL / ACCESS Newswire / July 20, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader implementing EinsteinRx™ artificial intelligence prescription drug routing into blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription medicines reimbursement and dispensing journey, today announced an updated record date for the distribution of the Dream Bowl 2026 Meme Coin (https://www.biconomy.com/exchange/DREAM1_USDT) to Wellgistics stockholders. On December 3, 2025, Wellgistics announced that it would distribute one (1) Dream Bowl 2026 Meme Coin for every one (1) share of Wellgistics Health common stock held as of a designated record date.

Rubenstein PR named AOR for Wellgistics Health (WGRX) to launch its AI Healthcare ecosystem, expanding EinsteinRx & PharmacyChain for advanced Health IT.

Experienced Healthcare Information Technology Specialist Joins Leading Pharmaceutical IT Company TAMPA, FL / ACCESS Newswire / July 15, 2026 / Wellgistics Health, Inc. (the "Company" or "Wellgistics") (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™, today announced that it appointed healthcare information technology executive Brett Thompson as the Company's consulting Chief Technology Officer (CTO). Mr. Thompson has more than thirty years of experience designing, developing, and leading enterprise software solutions, including more than seventeen years focused on healthcare and pharmacy technology.

Executives exercise previously issued warrants to acquire 200,000 common shares Shares issued in connection with exercise added to existing lock-up agreements TAMPA, FL / ACCESS Newswire / June 30, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™ , today announced that its Executive Chairman Suren Ajjarapu and President & Interim Co-CEO Prashant Patel have exercised all warrants previously issued to them in connection with the conversion of their outstanding salaries into common shares at $10 per share. The exercise of the warrants resulted in the issuance of a total of 200,000 to the executives.

Name reflects vertically-aligned healthcare ecosystem business model integrating data captured via telemedicine, online pharmacy, lab tests and wearables to perfect patients' digital health twins in the Health Lives Here app designed to influence/optimize behavior EinsteinRx AI™ capabilities expanding into medical, laboratory and wearables fields Pharmacy and Pharmacy Services division being rebranded as Corexa Health™ Company positioned to empower patients to seize ownership of their health data with blockchain-enabled data management to control data and participate in its monetization (1) 2,647,198 common shares outstanding, with (2) 1,333,930 of those shares locked up for at least ninety (90) days from today, and (3) 919,465 common shares deposited in DTCC, leaving (4) 80,628 cash warrants with fixed $35.00 exercise price representing only other securities currently eligible for deposit into DTCC for free trading shares TAMPA, FL / ACCESS Newswire / June 26, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™ , today announced that its management and Board of Directors has selected DataMeds AI, Inc as its new corporate name, subject to shareholder approval. The proposed new stock sticker remains MEDS.

Focus is on closing DelivMeds AI transaction, driving pharmacy revenue growth and supporting PharmacyChain™, Medical Drones and Health Lives Here progress Recent capital raise provides capital into late 2026, including meeting criteria for DelivMeds AI transaction funding closing condition Recent capital raise and debt restructuring preclude the Company from issuing shares for capital raising purposes until the earlier of seven (7) months from the transaction date and thirty (30) days after effectiveness of the resale registration statement covering the underlying securities. Recent lock-up agreement to limit shares available for sale into the market Exercise of warrants embedded in recent financing would provide funding through 2029 TAMPA, FL / ACCESS Newswire / June 1, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™, today provided a mid-year 2026 corporate outlook.

Holders of 1,333,930 common shares agree to minimum 90-day lock-up agreement TAMPA, FL / ACCESS Newswire / May 28, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™, today announced that holders of a 1,333,930 common shares, representing a majority of the outstanding common shares of the Company, have entered into a lock-up agreement that precludes the sale of their shares into the market for at least 90 days. "This lock-up agreement, when combined with the recent restructuring of our convertible liabilities and the raising of new funding, underscores the confidence our shareholders have in management to execute against our recently-disclosed vertically-integrated growth plan outlined in the Company's recent shareholder letter," said Wellgistics Health Interim Co-CEO Gerald Commissiong.

New oversubscribed $21 million convertible debt instrument ("New Debt") refinances all outstanding convertible debt, provides $6.5 million in new capital for working capital and general corporate purposes does not accrue interest and converts into common shares at $6.00 per share Automatic Exchange provision automatically converts the New Debt into Preferred Stock upon the effectiveness of a registration statement and attainment of shareholder approval for the creation of Preferred Stock The class of Preferred Stock that the New Convertible Debt exchanges into (the "Funding Preferred") converts into common shares at $50.00 per share New funds raised satisfy capital raising closing condition from Fully Binding Term Sheet with Datavault AI, EOS Technology Holdings, Scilex Pharma and HealthBridge Advisors TAMPA, FL / ACCESS Newswire / May 27, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™ , today announced that it completed a financing transaction through the issuance of a new $21 million convertible debt instrument (the "New Debt") that refinances all of its outstanding convertible debt and provides $6.5 million in fresh capital (the "New Money"). The offering was oversubscribed.